Cronos Group Inc. (CRON)
USD 1.77
(-0.28%)
USD 1.77
(-0.28%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -72.14 Million USD | -23.54% |
| 2022 | -91.26 Million USD | -366.76% |
| 2021 | -192.28 Million USD | 113.86% |
| 2020 | -70.4 Million USD | 88.61% |
| 2019 | -1.4 Billion CAD | -12000.09% |
| 2018 | -18.84 Million CAD | -1442.23% |
| 2017 | -5.35 Million CAD | 35.9% |
| 2016 | -1.17 Million CAD | 70.7% |
| 2015 | 559.96 Thousand CAD | -79.94% |
| 2014 | -3.25 Million CAD | -259.75% |
| 2013 | -619.47 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -13.49 Million USD | -11.03% |
| 2024 Q1 | -12.1 Million USD | 47.99% |
| 2023 Q4 | -17.46 Million USD | -1111.77% |
| 2023 Q2 | -20.3 Million USD | -100.51% |
| 2023 Q3 | -1.44 Million USD | 92.9% |
| 2023 Q1 | -10.12 Million USD | -2175.28% |
| 2023 FY | - USD | -23.54% |
| 2022 Q4 | -445 Thousand USD | 97.43% |
| 2022 Q3 | -17.34 Million USD | 23.11% |
| 2022 Q2 | -22.56 Million USD | -4.22% |
| 2022 FY | - USD | -366.76% |
| 2022 Q1 | -21.64 Million USD | -137.29% |
| 2021 Q3 | -49.73 Million USD | 9.09% |
| 2021 Q4 | 58.04 Million USD | 216.72% |
| 2021 Q1 | -41.1 Million USD | 27.46% |
| 2021 FY | - USD | 113.86% |
| 2021 Q2 | -54.7 Million USD | -33.09% |
| 2020 Q1 | -157.26 Million USD | 10.86% |
| 2020 Q3 | -36.15 Million USD | -20.42% |
| 2020 Q4 | -56.66 Million USD | -56.73% |
| 2020 FY | - USD | 88.61% |
| 2020 Q2 | -30.02 Million USD | 80.91% |
| 2019 Q4 | -176.42 Million CAD | 73.66% |
| 2019 Q3 | -669.86 Million CAD | -210.47% |
| 2019 Q2 | -215.76 Million CAD | -11167.35% |
| 2019 Q1 | 1.94 Million CAD | 124.54% |
| 2019 FY | - CAD | -12000.09% |
| 2018 Q2 | 809.76 Thousand CAD | 165.48% |
| 2018 Q1 | -1.23 Million CAD | -635.19% |
| 2018 Q3 | -3.26 Million CAD | -502.59% |
| 2018 FY | - CAD | -1442.23% |
| 2018 Q4 | -7.94 Million CAD | -143.7% |
| 2017 Q2 | -2 Million CAD | -524.8% |
| 2017 FY | - CAD | 35.9% |
| 2017 Q4 | 231.06 Thousand CAD | 68.19% |
| 2017 Q3 | 137.38 Thousand CAD | 106.85% |
| 2017 Q1 | -320.83 Thousand CAD | -355.2% |
| 2016 Q1 | -324.82 Thousand CAD | 11.42% |
| 2016 Q3 | -424.94 Thousand CAD | -16.56% |
| 2016 Q2 | -364.56 Thousand CAD | -12.23% |
| 2016 Q4 | -70.48 Thousand CAD | 83.41% |
| 2016 FY | - CAD | 70.7% |
| 2015 Q2 | -417.39 Thousand CAD | 25.38% |
| 2015 Q4 | -366.68 Thousand CAD | -14.8% |
| 2015 FY | - CAD | -79.94% |
| 2015 Q3 | -319.4 Thousand CAD | 23.47% |
| 2015 Q1 | -559.38 Thousand CAD | 0.0% |
| 2014 Q3 | -76.68 Thousand CAD | -697.61% |
| 2014 Q2 | -9613.92 CAD | 0.0% |
| 2014 FY | - CAD | -259.75% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 123.4% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -2968.851% |
| Embecta Corp. | 245.4 Million USD | 129.401% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 144.291% |
| PainReform Ltd. | -9.56 Million USD | -653.987% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -1786.535% |
| SCYNEXIS, Inc. | 73.47 Million USD | 198.19% |
| Journey Medical Corporation | 1.92 Million USD | 3855.804% |
| Safety Shot Inc | -12.18 Million USD | -492.104% |
| Alpha Teknova, Inc. | -25.53 Million USD | -182.505% |
| Bright Green Corporation | - USD | Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 169.356% |
| Alvotech | -484.86 Million USD | 85.12% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 165.998% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 6203.976% |
| Cosmos Health Inc. | -17.06 Million USD | -322.869% |
| Dynavax Technologies Corporation | 9.66 Million USD | 846.42% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 51.935% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 54.581% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -1786.535% |
| Theratechnologies Inc. | -10.31 Million USD | -599.606% |
| Harrow Health, Inc. | 9.72 Million USD | 842.045% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -1494.453% |
| Biofrontera Inc. | -18.45 Million USD | -290.988% |
| DURECT Corporation | -24.68 Million USD | -192.291% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 173.425% |
| OptiNose, Inc. | -15.55 Million USD | -363.891% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 92.199% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -99.958% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 374.684% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 300.241% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -1739.431% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -10049.68% |
| Radius Health, Inc. | 38.31 Million USD | 288.329% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -2144.089% |
| ProPhase Labs, Inc. | -14.82 Million USD | -386.606% |
| Phibro Animal Health Corporation | 84.6 Million USD | 185.275% |
| Procaps Group S.A. | 104.02 Million USD | 169.356% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -758.814% |
| Viatris Inc. | 3.51 Billion USD | 102.052% |
| Rockwell Medical, Inc. | -4.69 Million USD | -1437.047% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -7029.348% |
| SIGA Technologies, Inc. | 84.15 Million USD | 185.729% |
| Tilray Brands, Inc. | -72.84 Million USD | 0.953% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 8985.345% |
| Shineco, Inc. | -26.55 Million USD | -171.708% |
| PetIQ, Inc. | 81.48 Million USD | 188.542% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -1894.373% |
| Incannex Healthcare Limited | -18.5 Million USD | -289.91% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 117.339% |
| Alimera Sciences, Inc. | 7.27 Million USD | 1091.603% |
| Silver Spike Investment Corp. | 7.34 Million USD | 1082.942% |
| Assertio Holdings, Inc. | -222.44 Million USD | 67.566% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -1707.952% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -1612.992% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -329.356% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -260.191% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 51.618% |
| Hempacco Co., Inc. | -12.77 Million USD | -464.844% |
| Talphera, Inc. | -9.84 Million USD | -633.073% |
| Alvotech | -484.86 Million USD | 85.12% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 193.093% |
| Lantheus Holdings, Inc. | 491 Million USD | 114.694% |
| Currenc Group, Inc. | -1.9 Million USD | -3696.169% |
| Kamada Ltd. | 21.53 Million USD | 435.047% |
| Indivior PLC | 66 Million USD | 209.317% |
| Evoke Pharma, Inc. | -7.29 Million USD | -889.387% |
| Flora Growth Corp. | -45.87 Million USD | -57.29% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -260.191% |
| Evolus, Inc. | -41.81 Million USD | -72.564% |
| HUTCHMED (China) Limited | 25.52 Million USD | 382.627% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 129.88% |
| Akanda Corp. | -27.73 Million USD | -160.131% |